DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Delayed price. Currency in USD
1.20
+0.03 (+2.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close1.17
Open1.17
Bid0.70 x 2000
Ask1.46 x 100
Day's range1.15 - 1.20
52-week range0.74 - 2.17
Volume468,911
Avg. volume973,245
Market cap178.255M
Beta2.06
PE ratio (TTM)N/A
EPS (TTM)-0.14
Earnings date12 Mar 2018 - 16 Mar 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1.97
Trade prices are not sourced from all markets
  • Marketwired4 months ago

    Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia

    A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.Included in this article is: DURECT Corp. In an Oct. 2 press release, ...

  • Reuters - UK Focus9 months ago

    NASH: The next untapped pharma market gives investors many options

    Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. With (Other OTC: WWTH - news) intense competition and pricing pressure eroding sales of medicines for diabetes, rheumatoid arthritis and other lucrative disease categories, and an already crowded field for developmental cancer drugs, big pharma sees NASH as an enormous new market for future profit that will accelerate a wave of deal making. Bristol-Myers Squibb also confirmed it is looking for additional assets to enhance its internally-developed NASH drugs.

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes